Montag A & Associates Inc. Has $11.03 Million Position in Stryker Corporation $SYK

Montag A & Associates Inc. grew its holdings in shares of Stryker Corporation (NYSE:SYK) by 5.5% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 34,949 shares of the medical technology company’s stock after purchasing an additional 1,837 shares during the period. Montag A & Associates Inc.’s holdings in Stryker were worth $11,034,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Norges Bank acquired a new stake in shares of Stryker in the fourth quarter valued at about $1,822,272,000. Auto Owners Insurance Co boosted its position in Stryker by 35,047.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock valued at $1,024,444,000 after purchasing an additional 2,906,448 shares during the last quarter. Wellington Management Group LLP boosted its position in Stryker by 22.6% during the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after purchasing an additional 1,198,665 shares during the last quarter. Corient Private Wealth LLC grew its stake in Stryker by 104.4% in the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after purchasing an additional 1,146,998 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its position in shares of Stryker by 241.9% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,555,638 shares of the medical technology company’s stock worth $511,167,000 after purchasing an additional 1,100,673 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on SYK shares. Sanford C. Bernstein set a $410.00 price objective on Stryker in a research note on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 target price on shares of Stryker in a research note on Friday, May 1st. Citizens Jmp lowered their target price on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating on the stock in a report on Monday, August 3rd. Wolfe Research lowered shares of Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday. Finally, Robert W. Baird set a $385.00 price target on shares of Stryker in a research note on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and an average price target of $386.28.

Stryker Trading Down 0.7%

Shares of NYSE:SYK opened at $338.80 on Friday. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86. The business has a 50 day moving average of $324.61 and a 200-day moving average of $333.57. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The stock has a market cap of $129.95 billion, a PE ratio of 35.11, a P/E/G ratio of 2.16 and a beta of 0.76.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the company earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities research analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.